熱門資訊> 正文
学者洛克被列入韦德布什的最佳创意名单
2026-09-26 01:17
- Scholar Rock Holding(SRRK) 0
- Invesco Strategic Emerging Markets ETF(ISEM) 0
- iShares收益最佳化債券ETF(BYLD) 0
- Outperform-rated Scholar Rock Holding Corp. (SRRK) has been added to Wedbush's Best Ideas List as it is "uniquely positioned to deliver a durable, de-risked commercial ramp in the neuromuscular space."
- The firm has a $70 price target (44% upside based on Sept. 24 close).
- Analyst David Nierengarten said that the company is being helped by Isembyld's (apitegromab) first-in-class launch for spinal muscular atrophy and its myostatin pipeline.
- He noted that a recent pullback in shares, likely due to a US FDA post-marketing safety commitment for Isembyld and lower-than-expected pricing, provides an attractive entry point.
- Nierengarten sees Isembyld US revenue of ~$5M this year, rising to $140M in 2027, $349M in 2028, and $634M in 2029. Worldwide revenue could surpass $2B by 2031.
- He added that studies examining Isembyld in SMA patients under the age of two years old and for facioscapulohumeral muscular dystrophy could provide additional upside.
More on Scholar Rock
- Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play
- Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
- Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy
- Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy
推薦文章
一周財經日曆 | 俄美烏三方會談、中美通脹數據重磅來襲！ANT估值或縮水至1萬億美元；遠信儲能領銜7只新股下周上市
美股前瞻 | 特朗普：我100%支持「超級智能」！AI硬件絕地反擊，閃迪盤前暴拉11%；10月非農遠高於預期！市場加大美聯儲12月加息押注
市場過度定價「藍色海嘯」？30只晶片股中有28只步入熊市！現在是否是「抄底時刻」？
港股異動 | AI硬件股遭重挫！南方兩倍做多海力士、南方兩倍做多三星跌約15%，長飛光纖光纜、劍橋科技、建滔積層板跌逾10%
中期選舉后，特斯拉與SpaceX市值合計蒸發逾4500億美元，馬斯克身價跌破8000億美元
美股慘遭2020年以來最嚴重暴跌 五張圖展示讓人無處可躲的衝擊波
中期選舉后民主黨高層呼籲限制人工智能產業擴張：「立即暫停全國數據中心建設」
芯片股慘遭重挫，華爾街迎來1896年以來中期選舉后表現最差的第二個交易日
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
